Controlling protein production in brain cells could help treat Parkinson’s Date 19 May 2021 New research has been published that sheds an important light on how the production of a key protein in the brain is controlled This could pave the way for new treatments for a wide range of neurological conditions.
Scientists move closer to developing ‘game-changing’ test to diagnose Parkinson’s Date 10 March 2021 Research shows it’s possible to identify Parkinson’s based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
We're investing £1.2m into drug that could slow Parkinson's Date 9 March 2021 We’re investing up to £1.2m into pioneering research in partnership with the University of Sheffield, which aims to develop a drug to protect dopamine-producing brain cells.
Caption Christine Proctor - participant in the GDNF trial Why we’re committing £800,000 to plan a new GDNF trial Date 23 February 2021 The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Further clues about alpha-synuclein Date 11 February 2021 New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
Vision tests predict cognitive decline linked to Parkinson's Date 19 January 2021 Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
New guidance for lab-based researchers on patient and public involvement Date 8 January 2021 We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
New trial to drive forward promising treatment for dyskinesia Date 22 November 2020 Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.
Caption Husband and wife look out the window Could an anti-sickness drug treat hallucinations in Parkinson's? Date 25 October 2020 We're funding a new research study into a possible treatment for hallucinations in Parkinson's.
Research finds air pollution may speed up Parkinson's Date 19 October 2020 Researchers in the US have uncovered a link between long-term exposure to pollution and deterioration in health conditions. This includes Parkinson's and Alzheimer's.
